Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | C1S | P09871 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316444 | 0.84 | PTPN1 (0.50) | PTPN1C1SALDH1A1HSD17B10HSD17B1 | |
| SCHEMBL15090492 | 0.81 | HSD17B1 (0.58) | PTPN1C1SALDH1A1HSD17B1HSD17B2 | |
| SCHEMBL185735 | 0.79 | HSD17B1 (0.61) | PTPN1ALDH1A1HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL30987375 | 0.78 | PTPN1 (0.50) | PTPN1C1SALDH1A1HSD17B10HSD17B1 | |
| SCHEMBL28745186 | 0.78 | PTPN1 (0.50) | PTPN1C1SALDH1A1HSD17B10HSD17B1 | |
| SCHEMBL10013448 | 0.77 | HSD17B1 (0.61) | PTPN1ALDH1A1HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL186863 | 0.77 | HSD17B1 (0.61) | PTPN1ALDH1A1HSD17B1HSD17B2CYP3A4 | |
| Bromide SCHEMBL11463626 | 0.77 | HSD17B1 (0.59) | PTPN1ALDH1A1HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL31312542 | 0.77 | HSD17B1 (0.53) | PTPN1ALDH1A1HSD17B10HSD17B1HSD17B2 | |
| SCHEMBL20379368 | 0.77 | HSD17B1 (0.53) | PTPN1ALDH1A1HSD17B10HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2215066-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058348-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058348-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039847-A1 | AMIDE DERIVATIVES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PTPN1 4321/4885C1S 4812/4885ALDH1A1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.